Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study

Annals of Oncology ◽

10.1093/annonc/mdw369.29 ◽

2016 ◽

Vol 27 ◽

pp. vi145

Author(s):

J. Capdevila ◽

A. Teulé ◽

J. Barriuso ◽

D. Castellano ◽

C. Lopez ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Gastrointestinal Neuroendocrine Tumours

Download Full-text

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study

European Journal of Cancer ◽

10.1016/j.ejca.2019.09.021 ◽

2019 ◽

Vol 123 ◽

pp. 92-100

Author(s):

Thomas Walter ◽

Come Lepage ◽

Romain Coriat ◽

Emilie Barbier ◽

Guillaume Cadiot ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Arterial Embolisation ◽

Gastrointestinal Neuroendocrine Tumours

Download Full-text

Everolimus after Hepatic Arterial Embolisation Therapy of Metastases from Gastrointestinal Neuroendocrine Tumours: The FFCD 1104-EVACEL-GTE Phase II Study

SSRN Electronic Journal ◽

10.2139/ssrn.3307654 ◽

2018 ◽

Author(s):

Thomas Walter ◽

C. Lepage ◽

R. Coriat ◽

E. Barbier ◽

G. Cadiot ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Arterial Embolisation ◽

Gastrointestinal Neuroendocrine Tumours

Download Full-text

A randomised phase II study comparing capecitabine plus streptozocin with or without cisplatin in the treatment of unresectable or metastatic gastroentero-neuroendocrine tumours of the foregut, pancreatic neuroendocrine tumours and neuroendocrine tumours of unknown primary site

http://isrctn.org/> ◽

10.1186/isrctn35124268 ◽

2012 ◽

Author(s):

Pippa Corrie

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Primary Site ◽

Unknown Primary ◽

Unknown Primary Site ◽

Pancreatic Neuroendocrine Tumours

Download Full-text

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

British Journal of Cancer ◽

10.1038/bjc.2013.470 ◽

2013 ◽

Vol 109 (6) ◽

pp. 1414-1419 ◽

Cited By ~ 47

Author(s):

H K Ahn ◽

J Y Choi ◽

K-M Kim ◽

H Kim ◽

S-H Choi ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Gastroenteropancreatic Neuroendocrine Tumours

Download Full-text

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-010-1631-x ◽

2010 ◽

Vol 38 (2) ◽

pp. 302-311 ◽

Cited By ~ 114

Author(s):

Phillip G. Claringbold ◽

Paul A. Brayshaw ◽

Richard A. Price ◽

J. Harvey Turner

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study

Download Full-text

718 ORAL Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81013-4 ◽

2005 ◽

Vol 3 (2) ◽

pp. 204 ◽

Cited By ~ 3

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Sunitinib Malate

Download Full-text

A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours

Journal of Nuclear Medicine ◽

10.2967/jnumed.121.261936 ◽

2021 ◽

pp. jnumed.121.261936

Author(s):

Irene Virgolini ◽

Shadfar Bahri ◽

Andreas Kjaer ◽

Henning Gronbaek ◽

Peter Iversen ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Imaging Agent ◽

Dosing Regimen ◽

Optimal Dosing ◽

Gastroenteropancreatic Neuroendocrine Tumours

Download Full-text

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

BMC Cancer ◽

10.1186/1471-2407-13-427 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 41

Author(s):

Marta Martín-Richard ◽

Bartomeu Massutí ◽

Eva Pineda ◽

Vicente Alonso ◽

Maribel Marmol ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Open Label ◽

Antiproliferative Effects ◽

Well Differentiated ◽

Lanreotide Autogel

Download Full-text

2269 [177Lu-DOTA]-D-Phe1-Tyr3-octreotide (177Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A retrospective phase II study of efficacy and safety

European Journal of Cancer ◽

10.1016/s0959-8049(16)31185-6 ◽

2015 ◽

Vol 51 ◽

pp. S422-S423

Author(s):

R.P. Baum ◽

A.K. Kluge ◽

H.R. Kulkarni ◽

M. Sayeg ◽

U. Schorr-Neufing ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Efficacy And Safety ◽

Peptide Receptor

Download Full-text

177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)

Annals of Oncology ◽

10.1093/annonc/mdz256 ◽

2019 ◽

Vol 30 ◽

pp. v564

Author(s):

A J A T Braat ◽

R. van Rooij ◽

R.C.G. Bruijnen ◽

M N G J A Braat ◽

F. Wessels ◽

...

Keyword(s):

Phase Ii ◽

Neuroendocrine Tumours ◽

Phase Ii Study ◽

Single Center ◽

Open Label ◽

Open Label Phase

Download Full-text